MaxCyte Inc MXCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
-
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
-
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
-
MaxCyte Reports Second Quarter 2026 Financial Results
-
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Trading Information
- Previous Close Price
- $1.30
- Day Range
- $1.28–1.32
- 52-Week Range
- $0.64–1.81
- Bid/Ask
- $1.28 / $1.29
- Shares Outstanding
- 103.21M
- Market Cap
- $134.17M
- Volume/Avg
- 1M / 830,226
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 91
- Website
- https://www.maxcyte.com
Valuation
|
Metric
|
MXCT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.64 |
Price/Sales | 3.32 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MXCT
|
|---|---|
Quick Ratio | 11.08 |
Current Ratio | 12.26 |
Interest Coverage | — |
Quick Ratio
MXCT
Profitability
|
Metric
|
MXCT
|
|---|---|
Return on Assets (Normalized) | −11.76% |
Return on Equity (Normalized) | −13.73% |
Return on Invested Capital (Normalized) | −15.66% |
Return on Assets
MXCT
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|?#nt>l | LOCK|sg%!< | $181B | |||
| Medtronic PLC
MDT
| LOCK|CSD#P< | LOCK|#Vc% | $121B | |||
| Stryker Corp
SYK
| LOCK|Jnh<>^T | LOCK|<N | $113B | |||
| Boston Scientific Corp
BSX
| LOCK|@RYw!S | LOCK|y!>% | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|vpKL%TT | LOCK|@%mv | $50B | |||
| DexCom Inc
DXCM
| LOCK|&cQyJ%fP | LOCK|wc>Tv | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|@&wb#sc | LOCK|tq | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|p^ | LOCK|Vf$ | $25B | |||
| Steris PLC
STE
| LOCK|<FW&<@@ | LOCK|<q^W | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|DW#<&&<M | LOCK|B$ | $18B |
United States